Pulmonary Artery Stent System Market
The market for Pulmonary Artery Stent System was estimated at $630 million in 2024; it is anticipated to increase to $849 million by 2030, with projections indicating growth to around $1.09 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Pulmonary Artery Stent System Market Outlook
Revenue, 2024
$630M
Forecast, 2034
$1.04B
CAGR, 2025 - 2034
5.1%
The Pulmonary Artery Stent System industry revenue is expected to be around $662.3 million in 2025 and expected to showcase growth with 5.1% CAGR between 2025 and 2034. The consistent expansion of the market for Pulmonary Artery Stent System reflects its growing importance in treatments today. This rise can be credited to a range of factors including advancements and the increasing occurrence of pulmonary artery diseases among an aging population. Additionally there is a rising demand for invasive medical procedures that further contribute to the markets significance, in modern healthcare.
The latest medical tool called the Pulmonary Artery Stent System helps widen or clear up blockages in the arteries to improve blood flow to the lungs smoothly and efficiently. With its qualities like being body friendly and strong with low rates of artery re narrowing after treatment make it a highly effective choice for dealing with conditions such, as Pulmonary Artery Hypertension and other related artery issues. This cutting edge system is mainly used in patient care and surgical procedures for better outcomes and patient well being.
Market Key Insights
- The Pulmonary Artery Stent System market is projected to grow from $630.2 million in 2024 to $1.04 billion in 2034. This represents a CAGR of 5.1%, reflecting rising demand across Chronic Thromboembolic Pulmonary Hypertension Management, Pulmonary Arteriovenous Malformation (PAVM) Procedure and Treatment of Pulmonary Artery Stenosis.
- Medtronic, Abbott Laboratories, Boston Scientific Corporation are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Pulmonary Artery Stent System market and are expected to observe the growth CAGR of 3.3% to 4.9% between 2024 and 2030.
- Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 5.9% to 7.0%.
- Transition like Technological Advancements in Pulmonary Artery Stent Systems has greater influence in U.S. and Germany market's value chain; and is expected to add $24 million of additional value to Pulmonary Artery Stent System industry revenue by 2030.
- The Pulmonary Artery Stent System market is set to add $406 million between 2024 and 2034, with manufacturer targeting Cardiac Clinics & Ambulatory Surgical Centers Applications/End-Users projected to gain a larger market share.
- With The increasing prevalence of pulmonary artery diseases, and Technological advancements, Pulmonary Artery Stent System market to expand 64% between 2024 and 2034.
Opportunities in the Pulmonary Artery Stent System
As technology advances further in the field with innovations such as bioabsorbable stents and drug eluting stents being integrated into the Pulmonary Artery Stent System; there is also potential for significant market growth for manufacturers, through enhanced patient outcomes and expanded market reach.
Growth Opportunities in North America and Asia-Pacific
North America is a player in the global medical field and holds promising opportunities for products like the Pulmonary Artery Stent System due to continuous technological progress and strong healthcare infrastructure in the region. The rising prevalence of diseases and an aging population susceptible to pulmonary issues make it crucial to embrace effective treatments like the Pulmonary Artery Stent Systems. The market competition is robust with renowned companies such as Medtronic and Abbott Laboratories playing a role, in shaping regional developments and progressing the system further. In North America the primary drivers of the market are the ability to spend in healthcare and the existence of medical device manufacturers.
The Asia Pacific region is experiencing growth in the market for Pulmonary Artery Stent Systems due to increasing cases of cardiovascular diseases and the demand for less invasive treatments in countries such as China, India and Japan. Health awareness and government efforts to improve healthcare standards are driving the adoption of medical devices, in this region. Both established companies and new entrants are vying for market share in a landscape that is fuelin g its growth. The thriving medical tourism sector in the Asia Pacific region is being fueled by factors such as a growing population and increased accessibility to treatments, like the Pulmonary Artery Stent System.
Market Dynamics and Supply Chain
01
Driver: The Increasing Prevalence of Pulmonary Artery Diseases
The increasing prevalence of artery conditions like pulmonary arterial hypertension and pulmonary embolism is also fueling the worldwide need for pulmonary artery stent systems. These stent systems play a role in restoring proper blood circulation and alleviating lung congestion for the expanding number of patients worldwide. Healthcare professionals favor the system due to its treatment regimen and minimally invasive nature. Factors that contribute to its rising popularity, in the market.
Recent advancements in stent technology have also been developed to address the limitations of stent systems and enhance the market for Pulmonary Artery Stent Systems significantly. The advancements in drug coated stents have also shown promising results in improving patient health outcomes by reducing complications and ensuring successful implantation procedures. This progress is also driving the demand for these solutions, in the crucial healthcare industry.
02
Restraint: High Cost of Pulmonary Artery Stent System
Due to the methods and premium materials used in creating the Pulmonary Artery Stent System—which accounts for its hefty price tag—the accessibility of these cutting edge systems is greatly hindered for numerous healthcare providers, in developing countries. Moreover insurance companies typically offer limited coverage for such specialized treatments causing potential users to hesitate due to high out of pocket expenses and thereby restraining market expansion.
03
Opportunity: Scope in Underdiagnosed Markets and Strategic Partnerships to Elevate Reach
In areas like Saharan Africa and Southeast Asia where Pulmonary Embolism detection is often missed out on significantly; there are great chances, for the growth of the Pulmonary Artery Stent System by making smart investments and bringing in affordable solutions to drive notable market expansion.
Creating beneficial bonds by forming strategic alliances with healthcare facilities and experts can significantly expand the market presence of the Pulmonary Artery Stent System. These partnerships offer avenues for additional clinical studies that can enhance system efficiency and facilitate its incorporation, into diverse treatment approaches.
04
Challenge: Lack of Skilled Professionals
The effective use of a Pulmonary Artery Stent System requires trained experts who possess not only the necessary medical expertise but also the technical know how to manage sophisticated equipment. However the shortage of proficient individuals is significant worldwide and is particularly acute, in rural and disadvantaged areas.
Supply Chain Landscape
1
Raw Material Suppliers
DupontDSM Biomedical
2
Component Manufacturers
MedtronicBoston Scientific
3
Producers
Abbott VascularCook Medical
4
End Users
HospitalsCardiac Centers
1
Raw Material Suppliers
DupontDSM Biomedical
2
Component Manufacturers
MedtronicBoston Scientific
3
Producers
Abbott VascularCook Medical
4
End Users
HospitalsCardiac Centers
Use Cases of Pulmonary Artery Stent System in Chronic Thromboembolic Hypertension Management & Arteriovenous Malformation (PAVM) Procedure
Chronic Thromboembolic Pulmonary Hypertension Management : In the field of managing diseases like pulmonary artery issues; the Pulmonary Artery Stent System has proven to offer notable advantages for patients in need of treatment for narrowed arteries caused by thromboembolic hypertension issues. This specific system involves using a balloon expandable stent to address artery constriction problems and aims to help healthcare professionals in easing patient discomfort and enhancing arterial performance overall. Prominent companies in this industry such as Medtronic and Boston Scientific have established their market presence by providing dependable and effective stent solutions, for medical practitioners and patients alike.
Treatment of Pulmonary Artery Stenosis : The use of the Pulmonary Artery Stent System with self expanding stents for treating Pulmonary Artery Stenosis has been crucial in practice as it helps widen narrowed or blocked arteries and improves blood flow back, to normal levels. Abbott Laboratories and Cook Medical are leading companies known for their precise stent technology in this field.
Pulmonary Arteriovenous Malformation (PAVM) Procedure : When dealing with Pulmonary Arteriovenous Malformation treatment options the Pulmonary Artery Stent System is commonly utilized. This may involve using metal stents that are covered to prevent blood flow. In this context companies, like Becton Dickinson and WL have been prominent players.
Recent Developments
The Pulmonary Artery Stent System has revolutionized the field of cardiology and brought about exciting advancements in healthcare services. This groundbreaking development has provided opportunities for the diagnosis and treatment of pulmonary artery issues. It is important to highlight that the reliability, safety and favorable results for patients have led to an expansion, in the industry of Pulmonary artery stent systems.
December 2024 : Medtronic Inc ramped up its efforts in research and development to unveil a Pulmonary Artery Stent System equipped with advanced AI features, for immediate diagnostic purposes.
October 2024 : Boston Scientific Corporation unveiled an updated Pulmonary Artery Stent System aimed to enhance results and shorten recovery periods.
July 2024 : Abbott Laboratories introduced its Pulmonary Artery Stent System in the European market providing improved biocompatibility and a variety of advanced customization features.
Impact of Industry Transitions on the Pulmonary Artery Stent System Market
As a core segment of the Medical Device industry,
the Pulmonary Artery Stent System market develops in line with broader industry shifts.
Over recent years, transitions such as Technological Advancements in Pulmonary Artery Stent Systems and Regulatory Shifts in the Pulmonary Artery Stent Systems Market have redefined priorities
across the Medical Device sector,
influencing how the Pulmonary Artery Stent System market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Technological Advancements in Pulmonary Artery Stent Systems
The medical equipment sector experienced a change from traditional stent devices to sophisticated pulmonary artery stent systems that brought about better results for patients and fewer complications in healthcare services delivery improved greatly as a result of these advanced stent systems. These advancements led to increased demand for these products which prompted improvements in production methods and distribution networks within the sectorresulted in a chain reaction of innovation and expansion in fields, like biotechnology manufacturing machinery and healthcare technology solutions.
02
Regulatory Shifts in the Pulmonary Artery Stent Systems Market
There have been changes in how new medical devices are approved and adopted due to the introduction of innovative pulmonary artery stent systems in the market recently. Strict regulations imposed by bodies like the FDA to ensure safety have led to more thorough product testing and increased transparency. These changes have had an impact on industries involved in medical devices such, as clinical trials operations and pharmaceutical manufacturing.